Bausch Health Companies Inc. (BHC)

Bausch Health is a leveraged specialty-pharma turnaround: FY2025 was its first profitable year since 2020, H1 2026 revenue grew 12% with operating cash flow up 80%, and the stock trades near 1.7x free cash flow with a roughly 59% FCF yield. Set against that are $20.2B of debt, negative shareholders' equity, an Altman Z-Score of 0.09, deep-junk credit ratings, an 8.5% average coupon and the 2027-2028 Xifaxan IRA/generic-entry cliff. SEC filings show covenant compliance, no going-concern conclusion and completed 2025-2026 refinancings, but the balance sheet dominates the picture. Fundamentally weak with elevated risks despite real operating improvement — a watchlist situation rather than a sound holding.

Absent near-term setup: the only in-window event is a trailing Bausch + Lomb pipeline readout (2026-08-25, announced confidence) whose reception is two-sided — Fierce Pharma reports Phase 2 flops on the Xiidra/Miebo programs against company framing of 'advancing' therapies — while the media sentiment delta is indeterminate (baseline enrichment timed out twice with <3 unique scored baseline items), retail is silent, and no forward-dated catalyst exists within 30 trading days. Red-Flag Screen clean with no cap applied; the Absent-setup floor (only a trailing neutral catalyst, empty forward calendar, indeterminate delta and retail) grounds a weak read.

Mixed chart quality: price 6.32 sits above the SMA50 (5.52) and SMA200 (5.85) with MACD line above zero (+0.28) and very strong ADX (46.98), confirming the larger July-August uptrend; but the stock is below its SMA20 (6.49) and EMA9 (6.49), Williams %R is -73.8 and the MACD histogram is negative (-0.08), so the pullback from the ~7.30 high is still in progress with no confirmed support reclaim. Score 3: some bullish, some weak signals — an intact larger uptrend digesting gains, but not yet a completed bullish setup. Score describes chart quality only; tradability is blocked by the upstream fundamental and qualitative floors.